09.05.2012 • News

Novozymes Now Supplying Pharmaceutical Grade Q7 cGMP Hyaluronic Acid

Novozymes Biopharma, part of Novozymes, has announced the first shipment of the company's Bacillus-derived hyaluronic acid, Hyasis, from its newly inaugurated manufacturing facility in China, which represents an investment of more than DKK 350 million.

The facility in Tianjin employs a patented water-based process to manufacture Hyasis to Q7 cGMP standards.

The first commercial products using Hyasis as a raw material are expected to reach the market in Q2 of this year.

 

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Top-Feature

most read